Investigational drug · Phase 3
VQW-765
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Social Anxiety Disorder (SAD).
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VQW-765"
First trial start
2025
Sep 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VQW-765", any sponsor or status.
Conditions studied
As listed on its trial records.
- Social Anxiety Disorder (SAD)
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "VQW-765" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPivotal-lookingActive, not recruiting
Vanda PharmaceuticalsIndustry
NCT07221578 · 500 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 2026
Drug: VQW-765; Placebo · For: Social Anxiety Disorder (SAD)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Encino, California · 30 sites in all
- Evaluating the Effects of VQW-765 vs. Placebo in Performance AnxietyPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04800237 · 230 participants · Start Feb 23, 2021 · Primary completion Aug 2, 2022
Drug: VQW-765; Placebo · For: Performance Anxiety
Sites: Tempe, Arizona; Beverly Hills, California; Garden Grove, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial: commentary, Baldwin et al.
Baldwin DS, Huneke NTM · Br J Psychiatry 2025
- Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial.
He Y, Polymeropoulos CM, Mohrman MA, et al. · Br J Psychiatry 2025
Also in development for Social Anxiety Disorder (SAD)
- FasedienolPhase 32 trials
VistaGen Therapeutics, Inc. · Social Anxiety Disorder, Social Anxiety Disorder (SAD)
- ONO-1110Phase 25 trials
Ono Pharmaceutical Co., Ltd. · Fibromyalgia, Social Anxiety Disorder (SAD), Major Depressive Disorder (MDD
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- NTX-1472Phase 21 trial
Newleos Therapeutics, Inc. · Social Anxiety Disorder (SAD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.